Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer
In the past few years, impressing improvements have been made in the treatment of advanced colorectal cancer. Following decades of modest achievements, in which it was just a matter of dose and schedule for 5-FU and leucovorin-the only treatment then available-first, the development of irinotecan an...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2011-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | In the past few years, impressing improvements have been made in the treatment of advanced colorectal cancer. Following decades of modest achievements, in which it was just a matter of dose and schedule for 5-FU and leucovorin-the only treatment then available-first, the development of irinotecan and oxaliplatin, and then the use of the two biologicals, bevacizumab and cetuximab, have dramatically improved the life expectancy of our colorectal cancer patients... |
|---|---|
| Item Description: | 10.4081/oncol.2009.1 1970-5557 1970-5565 |